Experienced in Mantle Cell Lymphoma (MCL)

Jochen Casper

Rahel Straus Str. 10, 
Oldenburg, NI, DE 
Experienced in Mantle Cell Lymphoma (MCL)
Rahel Straus Str. 10, 
Oldenburg, NI, DE 
OverviewLocationsClinical Research

Overview

Jochen Casper practices in Oldenburg, Germany. Mr. Casper is rated as an Experienced expert by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Recurrent Peripheral Facial Palsy, Melkersson-Rosenthal Syndrome, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

His clinical research consists of co-authoring 38 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Mantle Cell Lymphoma (MCL).

Gender
Male

Locations

Rahel Straus Str. 10, Oldenburg, NI 26133, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Dasatinib, Cytarabine, Daunorubicin, Idarubicin
Study Phase: Phase 3
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Enrollment Status: Completed
Publish Date: July 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

38 Total Publications

Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma.
Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma.
Journal: European journal of haematology
Published: September 18, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Casper's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile